The pipeline for drugs for control and elimination of neglected tropical diseases: 2. Oral anti-infective drugs and drug combinations for off-label usearticle Published on 2023-10-312024-09-05 Journal: Parasites & Vectors [Category] update2024, [키워드] Acedapsone albendazole amoxicillin Artemether artemisinins Arterolane artesunate Azithromycin azoles Balapiravir celgosivir Chloroquine clarithromycin Clavulanate CURE ID dapsone Diethylcarbamazine disulfiram doxycycline Drug reprofiling Drug repurposing fluconazole Imatinib Isavuconazonium itraconazole Ivermectin ketoconazole Levamisole Lumefantrine Mebendazole mefloquine Moxidectin moxifloxacin Neglected topical diseases nitazoxanide off-label use Oxamniquine Oxantel Piperaquine Posaconazole Praziquantel Pyrantel pamoate ravuconazole ribavirin rifampicin Rifapentine Sparfloxacin streptomycin Tribendimidine UV-4B [DOI] 10.1186/s13071-023-05909-8 PMC 바로가기 [Article Type] article
The African Kelleni’s roadmap using nitazoxanide and broad-spectrum antimicrobials to abort returning to COVID-19 square onearticle Published on 2023-06-162024-09-05 Journal: InflammoPharmacology [Category] update2024, [키워드] Broad-spectrum antimicrobials COVID-19 Kelleni’s protocol nitazoxanide Omicron variant SARS CoV-2 [DOI] 10.1007/s10787-023-01263-4 PMC 바로가기 [Article Type] article
Real-world practice of the Egyptian Kelleni’s protocol amid changing tropism of SARS-CoV-2 omicron BA.5.2.1.7, XBB 1.5 and CH.1.1 subvariants: a multi-purpose protocolCommentary Published on 2023-03-162024-09-05 Journal: Inflammopharmacology [Category] update2024, [키워드] Influenza Kelleni’s protocol loratadine nitazoxanide Norovirus RSV SARS-CoV-2 [DOI] 10.1007/s10787-023-01180-6 PMC 바로가기 [Article Type] Commentary
Therapeutic Potential of Salicylamide Derivatives for Combating Viral InfectionsArticle Published on 2023-03-052024-09-05 Journal: Medicinal research reviews [Category] update2024, [키워드] broad-spectrum antiviral agents Infectious diseases niclosamide nitazoxanide salicylamide derivatives [DOI] 10.1002/med.21940 PMC 바로가기 [Article Type] Article
Nitazoxanide and COVID-19: A reviewArticle Published on 2022-11-012022-11-15 Journal: Molecular biology reports [Category] SARS, 치료제, [키워드] Activation acute lung injury acute respiratory distress acute respiratory distress syndrome addition Anti-inflammatory anti-parasitic drug anti-SARS-CoV-2 Antiviral antiviral activity antiviral property ARDS autophagic cause cell death clinical trial Coronavirus disease 2019 COVID-19 Cytokine storm Cytokines distress drug effective finding IFN immunological in silico in vitro study Infection inflammatory disorders inflammatory reaction inhibit Innate immunity interferon lung mammalian mitigate Multi-organ damage nitazoxanide oxidative stress pathogenesis of SARS-CoV-2 pro-inflammatory cytokines Prospective Study Protozoa Rapamycin reduce Respiratory Coronavirus SARS-CoV-2 SARS-CoV-2 infections severe cases syndrome therapy Treatment triggered viral infections Viral pneumonia [DOI] 10.1007/s11033-022-07822-2 PMC 바로가기
Efficacy and safety of nitazoxanide in treating SARS-CoV-2 infection: a systematic review and meta-analysis of blinded, placebo-controlled, randomized clinical trialsArticle Published on 2022-11-012022-11-15 Journal: European Journal of Clinical Pharmacology [Category] SARS, 치료제, [키워드] 95% CI 95% confidence interval addition anti-inflammatory effect antiparasitic antiviral activity blinded clinical benefit continuous variable COVID-19 D-dimer D-dimer level death dichotomous variable Disease progression Effect effect size Efficacy and safety element eligibility enrolled Evidence Frequency ICU admission in vitro individual Inflammation Invasive mechanical ventilation lactate dehydrogenase LDH magnitude Meta-analysis Mild moderate Moderate COVID-19 nitazoxanide no difference Patient patients peer-reviewed performed Placebo placebo-controlled positive positive RT-PCR Primary outcome randomized clinical trial RCT RCTs receiving reducing reduction in reported risk SARS-CoV-2 SARS-COV-2 infection secondary outcome serum biomarker SMD standardized mean difference systematic review tested to define treat treated Viral load WBC were used White blood cell with COVID-19 [DOI] 10.1007/s00228-022-03380-5 PMC 바로가기
Randomized clinical trial of nitazoxanide or sofosbuvir/daclatasvir for the prevention of SARS-CoV-2 infectionArticle Published on 2022-09-302022-11-15 Journal: Journal of Antimicrobial Chemotherapy [Category] SARS, 치료제, [키워드] 95% CI adverse event antibody Antiviral effect ARMS clinical trial clinical trials control arm COVID-19 infection COVID-19 symptom criteria enrolled evaluated experimental arm Frequency had no healthcare worker high risk in vitro incidence rate Infection infection with SARS-CoV-2 nitazoxanide no significant difference participant PCR testing Poisson regression model positive SARS-CoV-2 PCR primary endpoint randomization Randomized randomized trial risk safety analysis SARS-CoV-2 SARS-COV-2 infection serology shown sofosbuvir/daclatasvir South Africa Symptoms the primary endpoint Treatment Trial was selected was used [DOI] 10.1093/jac/dkac266 PMC 바로가기
Pre-clinical evaluation of antiviral activity of nitazoxanide against SARS-CoV-2SARS-CoV-2에 대한 nitazoxanide의 항바이러스 활성의 전임상 평가Article Published on 2022-08-012022-09-11 Journal: EBioMedicine [Category] COVID19(2023년), SARS, 진단, 치료제, [키워드] affected animal animal model antiviral activity antiviral efficacy antiviral therapy archive clinical trial Complete Concentration COVID-19 demonstrated diffusion Diseases dosage drug effective Efficacy European European Virus Archive Global Evidence evidence of France hamsters Horizon Human Human airway epithelium humans impair in vitro Infectious diseases intranasal metabolite National nitazoxanide not effective organ organs pharmacokinetic Pre-clinical research reconstructed Research SARS-CoV-2 SARS-CoV-2 virus Support supported Therapeutics tizoxanide Treatment union viral replication Wellcome Trust [DOI] 10.1016/j.ebiom.2022.104148 PMC 바로가기 [Article Type] Article
Favipiravir and/or nitazoxanide: a randomized, double-blind, 2×2 design, placebo-controlled trial of early therapy in COVID-19 in health workers, their household members, and patients treated at IMSS (FANTAZE)Favipiravir 및/또는 nitazoxanide: IMSS(FANTAZE)에서 치료를 받는 의료 종사자, 가족 구성원 및 환자를 대상으로 한 COVID-19 조기 치료에 대한 무작위, 이중 맹검, 2x2 설계, 위약 대조 시험Randomized Controlled Trial Published on 2022-07-222022-09-11 Journal: Trials [Category] COVID19(2023년), SARS, 임상, 치료제, [키워드] 1:1 2×2 design absence Admission antimicrobial Antimicrobials Antiviral effect antiviral therapy Antiviral treatment antivirals appear assigned Asymptomatic blinded to treatment combination therapy Comorbidities Comorbidity Controlled trial COVID-19 COVID-19 disease disease double-blind early disease early phase early treatment example Favipiravir followed by Gender Genetic genetic mutation Health high risk Hospitalization Hypothesis in some include individuals Infection Inflammatory Influenza intensive care investigator investigators later phase morbidity and mortality Mutation mutation rate nitazoxanide obesity older patient outcome pandemic participant patients treated pharmacokinetics phase phase IIa Placebo placebo-controlled placebo-controlled clinical trial placebo-controlled trial positive presence or absence Prevent Primary outcome progression protocol randomised randomised controlled trial Randomized receive replicates SARS-CoV-2 secondary Secondary outcomes security Sepsis severe disease smoking status Social Security Stratification symptomatic symptomatic COVID-19 Symptoms tested the disease therapy those with comorbidity Toxicity treatment allocation Trial upper respiratory tract Viral load virus [DOI] 10.1186/s13063-022-06533-0 PMC 바로가기 [Article Type] Randomized Controlled Trial
Sofosbuvir/ledipasvir in combination or nitazoxanide alone are safe and efficient treatments for COVID-19 infection: A randomized controlled trial for repurposing antiviralsResearch article Published on 2022-05-012022-10-05 Journal: Arab Journal of Gastroenterology [Category] COVID19(2023년), SARS, 신약개발, 임상, 치료법, 치료제, [키워드] addition Antiviral approved clearance Combination COVID-19 COVID-19 infection Cox regression drug Efficacy and safety evaluated Factor Follow-up group highest Infection interval Mild moderate Mortality multicenter negative RT-PCR nitazoxanide Open-label Patient patients with COVID-19 polymerase chain primary endpoint Randomized Randomized controlled trial Result RT-PCR Safe SARS-CoV-2 SCT Serious Adverse Event significantly higher Sofosbuvir/ledipasvir standard care tested therapy three groups Treatment treatment for COVID-19 treatments for COVID-19 viral clearance viral clearance rate was done were recorded [DOI] 10.1016/j.ajg.2022.04.005 [Article Type] Research article